Symbols / SQZB $0.02 +0.00% SQZ Biotechnologies Company
SQZB Chart
About
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 707.79K | Enterprise Value | 11.99M | Income | -71.64M | Sales | 12.12M | Book/sh | 0.06 | Cash/sh | 0.35 |
| Dividend Yield | — | Payout | 0.00% | Employees | 53 | IPO | — | P/E | — | Forward P/E | -0.00 |
| PEG | — | P/S | 0.06 | P/B | 0.38 | P/C | — | EV/EBITDA | -0.20 | EV/Sales | 0.99 |
| Quick Ratio | 1.15 | Current Ratio | 1.37 | Debt/Eq | 1141.52 | LT Debt/Eq | — | EPS (ttm) | -2.43 | EPS next Y | -22.75 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2023-11-08 | ROA | -41.14% | ROE | -203.37% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -5.01% | Profit Margin | 0.00% | Shs Outstand | 29.49M | Shs Float | 26.14M | Short Float | 3.03% |
| Short Ratio | 27.26 | Short Interest | — | 52W High | 0.05 | 52W Low | 0.02 | Beta | 0.30 | Avg Volume | 1.74K |
| Volume | 25.00K | Target Price | — | Recom | None | Prev Close | $0.02 | Price | $0.02 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.02
Latest analyst target
3. DCF / Fair value
$-18.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.02
Low
—
High
—
Mean
—
- Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders - Business Wire hu, 29 Feb 2024 08
- SQZB Stock Price, News & Analysis - Stock Titan hu, 24 Apr 2025 22
- 7+ Companies That Had Their IPO in 2020: Best and Worst Performers - 24/7 Wall St. Sat, 06 Jan 2024 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Revenue |
|
21.03
-22.40%
|
27.10
|
| Operating Revenue |
|
21.03
-22.40%
|
27.10
|
| Operating Expense |
|
96.85
+1.03%
|
95.87
|
| Research And Development |
|
70.98
+1.19%
|
70.15
|
| Selling General And Administration |
|
26.32
+2.33%
|
25.72
|
| General And Administrative Expense |
|
26.32
+2.33%
|
25.72
|
| Salaries And Wages |
|
12.88
+1.58%
|
12.69
|
| Other Gand A |
|
13.43
+3.07%
|
13.03
|
| Other Operating Expenses |
|
-0.45
|
—
|
| Total Expenses |
|
96.85
+1.03%
|
95.87
|
| Operating Income |
|
-75.83
-10.26%
|
-68.77
|
| Total Operating Income As Reported |
|
-80.68
-17.33%
|
-68.77
|
| EBITDA |
|
-64.14
-11.09%
|
-57.74
|
| Normalized EBITDA |
|
-59.28
-2.67%
|
-57.74
|
| Reconciled Depreciation |
|
11.68
+5.93%
|
11.03
|
| EBIT |
|
-75.83
-10.26%
|
-68.77
|
| Total Unusual Items |
|
-4.86
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-4.86
|
0.00
|
| Special Income Charges |
|
-4.86
|
0.00
|
| Restructuring And Mergern Acquisition |
|
4.86
|
0.00
|
| Net Income |
|
-79.46
-15.60%
|
-68.74
|
| Pretax Income |
|
-79.46
-15.60%
|
-68.74
|
| Net Non Operating Interest Income Expense |
|
1.22
+3297.22%
|
0.04
|
| Net Interest Income |
|
1.22
+3297.22%
|
0.04
|
| Interest Income Non Operating |
|
1.22
+3297.22%
|
0.04
|
| Interest Income |
|
1.22
+3297.22%
|
0.04
|
| Other Income Expense |
|
-4.86
-60675.00%
|
-0.01
|
| Other Non Operating Income Expenses |
|
-0.00
+62.50%
|
-0.01
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-79.46
-15.60%
|
-68.74
|
| Net Income From Continuing Operation Net Minority Interest |
|
-79.46
-15.60%
|
-68.74
|
| Net Income From Continuing And Discontinued Operation |
|
-79.46
-15.60%
|
-68.74
|
| Net Income Continuous Operations |
|
-79.46
-15.60%
|
-68.74
|
| Normalized Income |
|
-74.61
-8.53%
|
-68.74
|
| Net Income Common Stockholders |
|
-79.46
-15.60%
|
-68.74
|
| Diluted EPS |
|
-2.76
-10.84%
|
-2.49
|
| Basic EPS |
|
-2.76
-10.84%
|
-2.49
|
| Basic Average Shares |
|
28.81
+4.47%
|
27.58
|
| Diluted Average Shares |
|
28.81
+4.47%
|
27.58
|
| Diluted NI Availto Com Stockholders |
|
-79.46
-15.60%
|
-68.74
|
| Line Item | Trend | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Assets |
|
99.90
-55.83%
|
226.15
|
| Current Assets |
|
68.20
-54.72%
|
150.63
|
| Cash Cash Equivalents And Short Term Investments |
|
63.71
-55.61%
|
143.51
|
| Cash And Cash Equivalents |
|
63.71
-55.61%
|
143.51
|
| Receivables |
|
0.38
-87.59%
|
3.10
|
| Accounts Receivable |
|
0.00
-100.00%
|
3.00
|
| Other Receivables |
|
0.38
+304.21%
|
0.10
|
| Prepaid Assets |
|
4.11
+2.09%
|
4.03
|
| Total Non Current Assets |
|
31.70
-58.03%
|
75.52
|
| Net PPE |
|
29.39
-59.68%
|
72.89
|
| Gross PPE |
|
35.17
-54.56%
|
77.40
|
| Accumulated Depreciation |
|
-5.78
-28.11%
|
-4.51
|
| Properties |
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
7.16
+2.59%
|
6.98
|
| Other Properties |
|
27.43
-60.72%
|
69.84
|
| Leases |
|
0.58
+0.00%
|
0.58
|
| Non Current Deferred Assets |
|
—
|
0.32
|
| Other Non Current Assets |
|
2.31
-12.29%
|
2.63
|
| Total Liabilities Net Minority Interest |
|
42.75
-58.16%
|
102.18
|
| Current Liabilities |
|
21.84
-34.26%
|
33.22
|
| Payables And Accrued Expenses |
|
11.99
+54.86%
|
7.74
|
| Payables |
|
2.51
-36.77%
|
3.97
|
| Accounts Payable |
|
2.51
-36.77%
|
3.97
|
| Current Accrued Expenses |
|
9.48
+151.38%
|
3.77
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.58
-15.20%
|
3.04
|
| Current Debt And Capital Lease Obligation |
|
6.56
-33.96%
|
9.94
|
| Current Capital Lease Obligation |
|
6.56
-33.96%
|
9.94
|
| Current Deferred Liabilities |
|
0.71
-94.28%
|
12.51
|
| Current Deferred Revenue |
|
0.71
-94.28%
|
12.51
|
| Total Non Current Liabilities Net Minority Interest |
|
20.91
-69.68%
|
68.95
|
| Long Term Debt And Capital Lease Obligation |
|
20.91
-65.01%
|
59.76
|
| Long Term Capital Lease Obligation |
|
20.91
-65.01%
|
59.76
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
9.20
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
9.20
|
| Stockholders Equity |
|
57.15
-53.90%
|
123.98
|
| Common Stock Equity |
|
57.15
-53.90%
|
123.98
|
| Capital Stock |
|
0.03
+3.57%
|
0.03
|
| Common Stock |
|
0.03
+3.57%
|
0.03
|
| Preferred Stock |
|
0.00
|
0.00
|
| Share Issued |
|
29.49
+4.83%
|
28.13
|
| Ordinary Shares Number |
|
29.49
+4.83%
|
28.13
|
| Additional Paid In Capital |
|
332.09
+3.96%
|
319.46
|
| Retained Earnings |
|
-274.97
-40.64%
|
-195.51
|
| Total Equity Gross Minority Interest |
|
57.15
-53.90%
|
123.98
|
| Total Capitalization |
|
57.15
-53.90%
|
123.98
|
| Working Capital |
|
46.36
-60.51%
|
117.41
|
| Invested Capital |
|
57.15
-53.90%
|
123.98
|
| Total Debt |
|
27.47
-60.58%
|
69.69
|
| Capital Lease Obligations |
|
27.47
-60.58%
|
69.69
|
| Net Tangible Assets |
|
57.15
-53.90%
|
123.98
|
| Tangible Book Value |
|
57.15
-53.90%
|
123.98
|
| Line Item | Trend | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Operating Cash Flow |
|
-83.55
-1.72%
|
-82.14
|
| Cash Flow From Continuing Operating Activities |
|
-83.55
-1.72%
|
-82.14
|
| Net Income From Continuing Operations |
|
-79.46
-15.60%
|
-68.74
|
| Depreciation Amortization Depletion |
|
11.68
+5.93%
|
11.03
|
| Depreciation |
|
11.68
+5.93%
|
11.03
|
| Depreciation And Amortization |
|
11.68
+5.93%
|
11.03
|
| Stock Based Compensation |
|
8.40
-1.20%
|
8.51
|
| Operating Gains Losses |
|
0.03
+371.43%
|
0.01
|
| Gain Loss On Sale Of PPE |
|
0.03
+371.43%
|
0.01
|
| Change In Working Capital |
|
-24.20
+26.51%
|
-32.94
|
| Change In Receivables |
|
3.00
+370.76%
|
-1.11
|
| Changes In Account Receivables |
|
3.00
+370.76%
|
-1.11
|
| Change In Prepaid Assets |
|
-0.37
-181.09%
|
0.46
|
| Change In Payables And Accrued Expense |
|
3.82
+383.31%
|
0.79
|
| Change In Accrued Expense |
|
5.25
+1953.36%
|
-0.28
|
| Change In Payable |
|
-1.42
-232.40%
|
1.07
|
| Change In Account Payable |
|
-1.42
-232.40%
|
1.07
|
| Change In Other Working Capital |
|
-20.99
+12.08%
|
-23.87
|
| Change In Other Current Assets |
|
0.32
+200.00%
|
-0.32
|
| Change In Other Current Liabilities |
|
-9.99
-12.44%
|
-8.88
|
| Investing Cash Flow |
|
-0.49
+20.39%
|
-0.61
|
| Cash Flow From Continuing Investing Activities |
|
-0.49
+20.39%
|
-0.61
|
| Net PPE Purchase And Sale |
|
-0.49
+20.39%
|
-0.61
|
| Purchase Of PPE |
|
-0.52
+14.85%
|
-0.61
|
| Sale Of PPE |
|
0.03
|
0.00
|
| Capital Expenditure |
|
-0.52
+14.85%
|
-0.61
|
| Net Investment Purchase And Sale |
|
—
|
0.00
|
| Sale Of Investment |
|
—
|
0.00
|
| Financing Cash Flow |
|
4.23
-92.43%
|
55.91
|
| Cash Flow From Continuing Financing Activities |
|
4.23
-92.43%
|
55.91
|
| Net Common Stock Issuance |
|
4.07
-92.79%
|
56.40
|
| Proceeds From Stock Option Exercised |
|
0.17
-88.23%
|
1.41
|
| Net Other Financing Charges |
|
—
|
-1.90
|
| Changes In Cash |
|
-79.80
-197.29%
|
-26.84
|
| Beginning Cash Position |
|
145.82
-15.55%
|
172.66
|
| End Cash Position |
|
66.01
-54.73%
|
145.82
|
| Free Cash Flow |
|
-84.07
-1.60%
|
-82.75
|
| Amortization Of Securities |
|
—
|
0.00
|
| Common Stock Issuance |
|
4.07
-92.79%
|
56.40
|
| Issuance Of Capital Stock |
|
4.07
-92.79%
|
56.40
|
| Net Preferred Stock Issuance |
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|